Canadian grants & funding programs

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)

This is a reissue of RFA-MH-18-701: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required). This FOA is a key element of NIMHs set of FOAs to support clinical trials research across the intervention development and testing pipeline. The FOA supports (1) clinical trials to test the effectiveness of optimized therapeutic and preventive interventions for use in community and practice settings; and (2) clinical trials to evaluate the effectiveness of patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of mental health services. This FOA is intended to support trials that: address a significant problem, such that the findings have potential to inform practice; are adequately powered to definitively answer the primary research question(s), with well-justified hypotheses supported by pilot data; and are designed to examine questions regarding mediators and moderators of effects. Consistent with the NIMH experimental therapeutics approach, this FOA is intended to support effectiveness trials that explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects (i.e., the mechanism(s) that accounts for changes in clinical/functional outcomes, changes in provider behavior, improved access or continuity of services, etc.). The collaborative R01 mechanism provides support for multisite trials when two or more sites are necessary for completion of the trial (e.g., to increase sample size, accelerate recruitment, or increase sample diversity and representation).

United States

NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required)

(Reissue of PAR-18-486) The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. NINDS will only accept applications to this FOA that propose human mechanistic trials/studies that meet NIH's definition of a clinical trial and that fall within the NINDS research priorities. Applicants are strongly advised to consult with NINDS program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.

United States

NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Clinical Trial Not Allowed)

The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-21-nnn.

United States

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required)

The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31.

United States

Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)

Reissue of PAR-19-147 This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.

United States

Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This FOA does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients. The proposed investigator-initiated projects should be related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences.

United States

Development of Animal Models and Related Materials for HIV/AIDS Research (R24 Clinical Trials Not Allowed)

The Office of Research Infrastructure Programs (ORIP) encourages grant applications aimed at developing, characterizing, or improving animal models for HIV/AIDS research or for improving access to information about or generated from the use of these specialized animal models for such research. The animal models, related biological materials, or technological tools to be developed must be broadly applicable to the scientific interests of two or more NIH Institutes or Centers (ICs) and must explore multiple body systems or evaluate diseases and processes that impact multiple body systems in order to align with ORIPs NIH-wide mission and programs as well as the research priorities of NIH Office of AIDS Research. Applications must describe the need for and the potential impact of the proposed resources on HIV/AIDS research. Applications for developing a limited number of resources or resources that will not have a broad impact on HIV/AIDS research will not be considered acceptable for this Funding Opportunity Announcement.

United States

NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

The Small Business Innovation Research (SBIR) Program is an important National Institutes of Health (NIH) funding mechanism used to develop innovative solutions that address public health challenges. A major objective of the SBIR Program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage. This gap is increased by the barriers associated with technologies under development for small commercial markets, such as those focused on rare diseases or young pediatric populations. This Funding Opportunity Announcement (FOA) invites small businesses to submit SBIR grant applications to support later stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR (Small Business Technology Transfer) Phase II awards that address rare diseases or young pediatric populations (aged 0-12 years and defined in Section IV, part 7), and will require eventual Federal regulatory approval/clearance. The goal of this FOA and the resulting Phase IIB awards is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between small business awardees and third-party investors and/or strategic partners, including patient advocacy organizations.

United States

NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)

The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independent dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical training in a dental specialty program at no more than 3 person-months effort (25% effort) in any year of the R00 phase.

United States

LPS Qubit Collaboratory (LQC)

The U.S. Army Research Office (ARO) in partnership with NSA’s Laboratory for Physical Science (LPS) is soliciting Incubator, Collaboration, and Fellowship research proposals for participation in the LPS Qubit Collaboratory (LQC). The mission of the LQC can be captured in three broad goals: 1) pursue disruptive fundamental research and enabling technologies with a focus on qubit development for quantum computing and other applications (such as sensing); 2) grow deep, collaborative partnerships to tackle the most difficult and relevant long-term problems in quantum information science and technology; and 3) build a quantum workforce of tomorrow through research experiences in government at LPS and at LQC partners. The LQC will offer a mechanism for collaborative research between LPS and academia, industry, FFRDCs, and Government Laboratories to advance foundational and transformative research on challenging problems that have hindered progress in quantum information processing and associated technologies.. . The goal of this BAA is to seek proposals that bring together expertise from the public and private sectors and their respective research infrastructures to advance solutions that may be best approached as a collaborative team. A Collaboratory is “a center without walls, in which the nation’s researchers can perform their research without regard to physical location, interacting with colleagues, accessing instrumentation, sharing data and computational resources, [and] accessing information in digital libraries. This BAA introduces LQC Research Thrusts (. . A.1.1. . ) which are the technical areas of interest—which will be updated periodically—where partners of the LQC will pursue joint research with LPS through Incubator (. . A.1.2. . ) and Collaboration (. . A.1.3. . ) collaborative agreements. The LQC BAA also fulfills the Government’s overarching interest--through the proposed research and on-site research experiences--in creating and training a workforce in quantum science and technology, generating pathways of solutions that feed technology development, establishing partnerships, and creating transition opportunities. In further support of training through research, . . Section A.1.4. . calls for Quantum Computing Research (QuaCR) Graduate and Postdoctoral Fellowships for US citizens working in areas of interest.. . Substantial progress on solving the most difficult and long-term Quantum Information Science & Technology (QIST) research problems that unleash further rapid progress in the field will constitute LQC success. Examples of such research problems include (but are not limited to): limits of performance due to device design, material selection, and/or control, the exploration of alternative qubit physics (e.g., different approaches to qubit encoding or types of gates) and lowering of barriers to such approaches, advances in materials that improve qubit gate fidelity, reducing the overhead of classical components in quantum information technology and optimizing classical performance, and the exploration of applications of quantum technologies to new domains.. . Three categories of proposals are sought for this BAA:. . 1.Incubator. . opportunities seek partnership proposals from single investigators and small research groups, including teaching colleges, who may have unique skillsets to contribute toward the pursuit of the research thrusts presented in A.1.1. Incubator proposals may also be the development of concepts into a detailed technical research approach to advance solution of problems of high interest to quantum information science research. Incubator proposals would avail themselves of the collaboration opportunities with LPS research staff and infrastructure made available at the Laboratory for Physical Sciences (LPS) to lay the groundwork for concepts that may be suitable for a Collaboratory proposal or responses to other DoD quantum information science research opportunities.. . 2.Collaboratory. . proposals seek research proposals that bring together a strong significant collaboration--researchers from academia, industry, FFRDCs, and/or Government Laboratories--to pursue long-term projects focused on fundamental problems of interest to qubit development and/or associated science and technology. These collaborative groups will propose to work together in a focused manner for a period of time expected to be one to three years in order to demonstrate a proof-of-concept experiment and/or theory exploration to determine the feasibility of their creative idea.. . 3.QuaCR Research Fellowship. . proposals seek to support talented U.S. citizen graduate students and postdoctoral researchers in the field of quantum information processing (primary interest) and quantum sensing (secondary interest). Applicants with a background from either within or outside QIS are encouraged. The proposed research areas are described in this BAA and must enhance active Quantum Information Science research efforts being supported by the Army Research Office and/or LPS. Research fellows are encouraged to complete an LPS Internship during their graduate career or visit during their postdoctoral fellowship

United States

Leveraging Health Information Technology (Health IT) to Address and Reduce Health Care Disparities (R01 Clinical Trial Optional)

This funding opportunity announcement (FOA) seeks to support research that examines the impact of leveraging health information technology (health IT) to reduce health care disparities in access to care, patient-clinician communication, and health outcomes for populations that experience health disparities in the U.S.

United States

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)

This is a reissue of RFA-MH-18-707: Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required). As part of NIMH's clinical trials pipeline FOAs, this announcement supports confirmatory efficacy testing of non pharmacological therapeutic and preventive interventions for mental disorders in adults and children that address unmet therapeutic needs, and are consistent with the NIMH emphasis on the experimental therapeutics approach. In this approach, clinical trials should be designed to increase knowledge of the relationship between underlying disease processes and the mechanisms of action through which any intervention produces therapeutic change.

United States

Focused Technology Research and Development (R01 Clinical Trial Not Allowed)

This initiative will support projects that focus solely on development of technologies with the potential to enable acquisition of basic biomedical knowledge. Projects should be justified in terms of technical innovation, and utility for future biomedical impact.The products of this research will be functioning prototype instruments, methods, synthetic approaches, biological products, etc., characterized adequately to be ready for first application to the type of biomedical research questions that provide the rationale for their development, but application of the proposed technology to specific biomedical questions is considered beyond the scope of the program, should not be included, and would not be funded.Proof of principle for the technology will have already been shown, but there will still be significant fundamental technical challenges. Applications should include preliminary data. Projects that have significant remaining risk but are supported by early feasibility studies might be appropriate for a three year R01 proposal with reduced budget to better manage risk and investment. Projects that are well supported by feasibility studies and propose to develop fully functional prototypes might require higher budgets and a four year duration (five years for early stage investigators). Projects that primarily focus on optimization, hardening, or obvious extrapolations of established technology might be less competitive.

United States

NINDS Postdoctoral Mentored Career Development Award (K01 No Independent Clinical Trial Allowed)

The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field.This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

United States

Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)

Reissue of RFA-MH-21-106 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work.

United States

NIDCR Predoctoral to Postdoctoral Transition Award for a Diverse Dental, Oral and Craniofacial Research Workforce (F99/K00 Independent Clinical Trial Not Allowed)

The purpose of the NIDCR Predoctoral to Postdoctoral Transition Award for a Diverse Dental, Oral and Craniofacial Research Workforce (F99/K00) is to support outstanding graduate students from diverse backgrounds, including those from groups underrepresented in biomedical, clinical, behavioral and social sciences, over the transition from predoctoral to postdoctoral research training. This phased award program will facilitate completion of graduate PhD or dual degree clinician scientist programs (F99) and progression to mentored postdoctoral positions in dental, oral and craniofacial research (K00). It is anticipated that successful completion of this phased award program will enable achievement of an independent research faculty position and subsequent NIDCR career development and research project awards. This Funding Opportunity Announcement (FOA) does not allow prospective fellows to propose to lead an independent clinical trial, but does allow prospective fellows to propose research experience in a clinical trial led by a sponsor or co-sponsor.

United States

Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional)

This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers.. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker Scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the Scholar can be considered to remain as an investigator within the intramural program.

United States

NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

The Small Business Innovation Research (SBIR) Program is an important funding mechanism that the National Institutes of Health (NIH) uses to develop innovative solutions that address public health challenges. A major objective of the SBIR Program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage. This Funding Opportunity Announcement (FOA) invites SBIR grant applications from SBCs to support later later-stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR Phase II awards and will require eventual Federal regulatory approval/clearance. The goal of this FOA and the resulting Phase IIB awards is to assist applicants in pursuing the milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between SBIR Phase II awardees and third-party investors and/or strategic partners.

United States

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)

The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.

United States

Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)

The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the l?e?a?d?i?n?g? ?e?d?g?e? of the field will change over time and will be updated annually through the NIH Guide to Grants and Contracts and hyperlinked to this FOA.

United States

NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed)

(Reissue of PAR-18-490) The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

United States

Fundamental Research to Understand the Mechanisms of Neurotropic Virus-mediated Disease (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to promote basic research to better understand the mechanisms underlying viral invasion of the central nervous system (CNS), virus- and/or host immune-mediated neuropathogenesis, and the associated clinical manifestations for emerging and re-emerging neurotropic viruses.

United States

NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 No Independent Clinical Trials)

The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-21-XXX).

United States

FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)

The purpose of the FDA (R13) Scientific Conference Grant Program is to facilitate the provision of federal financial assistance in support of high-quality conferences and scientific meetings designed to research and investigate a topic clearly aligned with the FDA mission. The FDA recognizes the value of supporting high quality conferences and scientific meetings relevant to its mission and to the public health. A conference or scientific meeting is defined as a symposium, seminar, workshop, or any formal meeting, whether conducted face-to-face or virtually to exchange information and explore a defined subject, issue, or area of concern impacting the public's health within the scope of the FDA's mission. Permission to submit a conference grant application does not assure funding or funding at the level requested. FDA will not issue a conference grant award unless it can be issued before the conference start date. 

United States

CSIRO Kick-Start

Up to 50% matched funding for eligible R&D costs, up to $50,000 per project.

Matched-funding grants to support R&D collaboration between Australian SMEs and CSIRO for product, process, or service development, testing, and prototyping.

Australia

Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites grant applications aimed at elucidating neuroimmune and neuronal-glial pathophysiological mechanisms of HIV-associated neurological disorders (HAND) using ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC) in the presence of addictive substances. Specific emphasis is on unbiased, reproducible analysis of genetics and epigenetics, neuroglial interactions, and neuroimmune cell activities from the single cell to neural circuit levels.

United States

Food Product Development Assistance

50% funding for product development, testing, and technical training in food innovation.

The program contributes 50 per cent of project costs to a maximum contribution of $50,000 per business. Multiple projects may be submitted by one business; however, the maximum approval amount to one business in a twelve month period will not exceed $50,000.

Prince Edward Island

Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to enhance the diversity of the pool of the cancer research workforce by recruiting and supporting eligible junior investigators and Early Stage Investigators from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical and social sciences. This funding opportunity will also provide a bridge to investigators who have completed their research training and may need extra time to develop a larger research project grant application.

United States

Ville de Québec – Fonds local d’investissement (FLI) – Innovation/Numérique Grants

Non-repayable contributions may be available up to $50,000 for innovation/digital projects via local funds (terms vary by MRC).

Supports businesses in Quebec City carrying out innovation and digital transformation initiatives, including software development, process digitization, and commercialization of new technologies.

Quebec City · Quebec

PME MTL – Innovation Program

Non-repayable contribution typically up to $50,000 for eligible innovation activities.

Non-repayable financial contribution to support the development of innovative products, services, or processes in the City of Montreal, including prototyping, validation, and early market testing.

Montreal · Quebec

City of Montreal – Technological Test Beds Program

Financial contribution for eligible pilot and demonstration costs, up to $50,000.

Supports companies that want to test innovative technologies in real-life environments on City of Montreal assets or with municipal partners. Ideal for pilots and demonstrations to validate solutions.

Montreal · Quebec

Yukon Government – Enterprise Trade Fund (ETF)

Covers up to 50% of eligible costs; maximum typically up to $50,000 per applicant per year.

Supports Yukon businesses undertaking market development and export activities, including marketing, trade shows, and commercialization planning for new products/services.

Yukon

Indigenous Forestry Initiative

The objective of the Indigenous Forestry Initiative (IFI) is to advance reconciliation in the forest sector by supporting Indigenous-identified priorities to accelerate Indigenous awareness, influence, inclusion, and leadership.

Canada

Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21) (Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

United States

Ethical, Legal and Social Implications (ELSI) (Research R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

United States

NEI Collaborative Clinical Vision Research Project: Resource Center Grant (UG1 Clinical Trial Required)

The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer, stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring. . For purposes of this Notice of Funding Opportunity (NOFO), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of single-component companion grant awards including the Chairs Grant, the Coordinating Center, and Resource Centers, when appropriate.. Specifically, this NOFO encourages applications for the Resource Center grant which provides imaging, laboratory, or other requisite services for a multi-center clinical trial or other complex or high-risk clinical trial.

United States

Limited Competition: Small Grant Program for ORIP Special Emphasis Research Career Award (SERCA) K01 Recipients (R03 Clinical Trials Not Allowed)

The Office of Research Infrastructure Programs (ORIP) within the Division of Program Coordination, Planning, and Strategic Initiatives announces an opportunity to apply for small grant support for ORIP-supported Special Emphasis Research Career Award (SERCA) K01 recipients who have completed the first two years (24 months) of the SERCA K01 award. ORIP seeks to enhance the ability of ORIP SERCA K01 awardees to conduct research as they transition to fully independent investigator status. The R03 mechanism supports projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support research projects that can realistically be completed in two years and that require limited levels of funding.. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).

United States

Green Industrial Facilities and Manufacturing Program – Energy Studies

Up to 50% of eligible costs for energy studies, up to $50,000 per study.

NRCan support for engineering studies that identify energy efficiency and GHG reduction opportunities in industrial facilities.

Canada

Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)

NCATS is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS. Please see Determination that a Public Health Emergency Exists Nationwide as the Result of the Opioid Crisis as renewed in Renewal of the Determination that a Public Health Emergency Exists Nationwide as the Result of the Continued Consequences of the Opioid Crisis.This Funding Opportunity Announcement (FOA) invites applications from early and mid-career investigators (i.e. postdoctoral fellow/associates associate professor) who strive to expand their research trajectories through the acquisition of new knowledge and skills in the areas of therapeutic drug, biologic, or device development.

United States

Canada Book Fund Publishers Business Development – Business Planning – Aboriginal or Official Language Minority Firms

70% funding for internships and business planning to boost your publishing success.

The Support for Publishers component of the Canada Book Fund (CBF) helps to ensure the sustainable production and marketing of Canadian-authored books by offsetting the high costs of publishing in Canada and building the capacity and competitiveness of the sector. The Business Development sub-component provides assistance to publishers for internship projects and business planning projects.

Canada

Healthy Hire Manitoba Program

70% funding for research, technology, and innovation to elevate Manitoba's economy.

The Government of Manitoba has announced a new hiring wage program that aims to encourage employees to get vaccinated and return to work. The program will offer active Manitoba-based businesses up to $5,000 per employee to a maximum $50,000 for 10 employees to help offset the wages of rehired or new employees who have received their COVID-19 vaccines or who can confirm that they have at least one vaccine booked.

Manitoba

Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)

The purpose of this funding opportunity announcement (FOA) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.

United States

Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support applications for epidemiological and observational research projects on the long-term cardiopulmonary sequelae following treatment for tuberculosis (TB). Investigators should propose additional testing and data collection in existing cohorts of adult and/or pediatric TB participants to better characterize and understand adverse outcomes and morbidity associated with TB disease post treatment in individuals with and without HIV infection.

United States

Indigenous Intellectual Property Program Grant – Project Stream

Up to 100% funding for Indigenous IP projects, travel, and capacity building.

The Indigenous Intellectual Property Program (IIPP) grant is designed to support increased engagement in the IP system by Indigenous peoples in Canada. The grant funds eligible Indigenous organizations to support participation in World Intellectual Property Organization (WIPO) sessions, small-scale initiatives and projects related to intellectual property (IP), Indigenous Knowledge (IK) and Indigenous Cultural Expressions (ICEs).

Canada

NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://www.niaid.nih.gov/research/role).

United States

Irrigation Efficiency Program

30% funding for upgrading irrigation systems, improving efficiency, and conserving water.

The program offers rebates of up to 30% of eligible costs, with a maximum payment of $50,000 over the program term, to enhance irrigation system efficiencies for agricultural producers in Saskatchewan.

Saskatchewan

Open Technology Fund – Rapid Response Fund

Up to $50,000 for rapid-response cybersecurity hardening, incident response, and critical infrastructure support.

Rolling emergency support to improve the security of the internet and users at risk. Funds short-term technical assistance, digital security improvements, incident response, and critical infrastructure hardening for organizations and projects facing urgent threats to freedom and privacy online.

Global · Canada

EnAbling Change Program (Ontario) – Industry Accessibility Projects

Funding support for development and dissemination of accessibility resources; amounts vary by project.

Funding for sector-wide accessibility education and tools developed by industry organizations to help Ontario businesses comply with AODA and improve accessibility for customers.

Ontario · Canada